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ABSTRACT
EPHA4 belongs to the largest subfamily of receptor tyrosine kinases. In addition 
to its function during development, overexpression of EPHA4 in tumors has been 
correlated with increased proliferation, migration and poor survival. Several genome-
wide transcription profiling studies have demonstrated high EPHA4 expression in 
Sézary syndrome (SS), a leukemic variant of cutaneous CD4+ T-cell lymphoma 
(CTCL) with an aggressive clinical course and poor prognosis. In this study we set 
out to explore the functional role of EPHA4 in SS. Both high EPHA4 mRNA and protein 
expression was found in circulating SS-cells of patients compared to healthy CD4+ 
T-cells. However, using a phosphospecific EPHA4 antibody, phosphorylation of the 
EPHA4 kinase domain was not detected in either circulating or skin residing SS cells. 
Moreover, treatment with the phosphatase inhibitor pervanadate did not result in 
detectable phosphorylation of the EPHA4 kinase domain, in either SS cells or in healthy 
CD4+ T-cells. Thus, the results from our study confirm high EPHA4 expression in SS 
cells both on the mRNA and protein levels, making EPHA4 a good diagnostic marker. 
However, the overexpressed EPHA4 does not appear to be functionally active and its 
overexpression might be secondary to other oncogenic drivers in SS, like STAT3 and 
TWIST1.
INTRODUCTION
Sézary syndrome (SS) is a rare leukemic variant of 
cutaneous T-cell lymphoma (CTCL) that is characterized 
by erythroderma, generalized lymphadenopathy, and the 
presence of neoplastic CD4+ skin-homing memory T-cells 
(SS cells) in the skin, lymph nodes, and peripheral blood.
[1-3]. Diagnosis is based on the clinical presentation, 
presence of SS cells in the skin, detection of clonally 
rearranged T-cell receptor (TCR) in both skin and 
peripheral blood, as well as on one or more aberrancies 
in the peripheral blood, such as an absolute count of > 
1000 SS cells mm3, a CD4 ⁄CD8 ratio of > 10, and loss 
of T-cell markers such as CD2, CD3 and ⁄or CD5 [2, 4]. 
In early stages of disease, differentiation between SS and 
benign erythroderma (BE) secondary to atopic dermatitis, 
chronic dermatitis, or adverse drug reactions, can be very 
difficult. SS often has an aggressive clinical course and 
poor prognosis (estimated 5-year survival < 25%) and 
until now, the results of various treatments for SS are 
generally disappointing.
Studies investigating the pathogenesis of SS 
demonstrated aberrations at both genomic [5, 6] and 
expression level, which have implicated pathogenic 
involvement of signaling pathways such as STAT [7-9] 
and NOTCH1 [10]. Three independent genome-wide gene 
expression studies all found high mRNA expression of the 
receptor tyrosine kinase (RTK), EPHA4, in SS but not in 
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other CTCLs or BEs [11-13]. This suggests that EPHA4 
might be a specific diagnostic marker and potentially, an 
attractive target for therapeutic intervention. 
EPH receptors are the largest subfamily of RTKs 
[14, 15]. In the human genome, fourteen EPH receptors 
have been identified, which can be divided in two 
classes, EPHA and EPHB receptors respectively, based 
on sequence similarities and ligand-binding properties. 
EPH receptors are activated by their cell surface-anchored 
ligands, so-called Ephrins. Ephrins are attached to the cell 
membrane either via a glycosylphosphatidylinositol (GPI) 
anchor linkage (A class) or a transmembrane sequence (B 
class). Since initial identification as important mediators 
during development of the central nerve system [16], 
EPH/Ephrin signaling was shown to be involved in many 
different cell-cell interactions and cellular processes [17-
19], with EPHA4 as an essential regulator in the correct 
guidance of spinal cord axons during development[16, 
20, 21]. Deregulation of EPH/Ephrin signaling has been 
demonstrated in a variety of diseases, including diabetes, 
neurodegenerative disorders and cancer [19, 22].
In addition to Sézary syndrome, EPHA4 has also 
been found to be overexpressed in several different 
types of solid tumors, such as prostate, pancreatic, liver 
and gastric cancer [23-26]. In gastric cancer EPHA4 
overexpression has been correlated with poor prognosis 
[24] and depletion of EPHA via siRNA resulted in 
decreased proliferation and lower migration [23, 27]. 
In contrast, EPHA4 has recently been described as an 
inhibitor of cell migration and invasion in lung cancer 
[28].
The aim of the current study was to explore the 
functional role of EPHA4 as a RTK in SS cells. We set out 
to confirm the previously observed high expression of both 
mRNA and protein and investigate if EPHA4 is active, by 
looking at phosphorylation of the kinase domain in both 
tumor cells in the peripheral blood and skin. Moreover, 
we investigated EPHA4 activation in vitro in SS cells and 
healthy CD4+ T-cells. 
RESULTS
EPHA4 is overexpressed in primary SS cells but 
not in SS cell lines
We previously demonstrated that EPHA4 mRNA 
is highly expressed in primary CD4+ cells of SS patients 
[11]. Here we extended this finding by investigating 
EPHA4 mRNA expression in SS cells of five new SS 
patients and compared that to four healthy controls and 
four BE samples (Figure 1A). We indeed could confirm 
that EPHA4 was significantly higher expressed in SS cells 
compared to healthy controls (p = 0.0079) and benign 
erythroderma (p = 0.0079). Interestingly, EPHA4 mRNA 
was not expressed in the two well known SS cell lines, 
HuT-78 and SeAx (Figure 1A).
To investigate if high EPHA4 mRNA expression 
was accompanied by increased protein expression, we 
performed Western blot analyses on eight primary SS 
samples and compared them to CD4+ T-cells from four 
healthy controls for the presence of EPHA4 protein 
(Figure 1B). EPHA4 protein could be detected in both 
SS samples and healthy controls. However the amount of 
EPHA4 protein in the primary SS cells was higher than 
in the CD+ T-cells from healthy controls. Consistent with 
Figure 1: EPHA4 and phosphorylated EPHA4 
expression in SS. A. RNA was extracted from CD4+ T-cells 
isolated from peripheral blood from five SS patients, four benign 
erythroderma samples (BE) and the SS cell lines SeAx and HuT-
78. EPHA4 expression was assayed by qPCR and normalized 
for expression of the stably expressed reference genes ARF5, 
ERCC3 and TMEM87A using geNorm [32]. Each symbol 
represents the expression in an individual patient, and the 
horizontal line represents the median expression in the group. 
Statistically significant differences (p < 0.05; Mann-Whitney 
test) are indicated. B. Protein lysates from CD4+ T-cells isolated 
from peripheral blood from eight SS patients and four healthy 
controls were analyzed with Western blot for the presence of 
EPHA4 protein and EPHA4 phosphorylated at Y779 in the 
kinase domain (pEPHA4-Y779). The EPHA4 expression was 
compared to that in PC3 cells untreated (untr.) or treated with 
pervandate (perv.). β-actin served as loading control. C. Protein 
lysates of the SS cell lines SeAx and HuT-78 were subjected to 
Western blot analysis using EPHA4 antibody and expression was 
compared to that in PC3 cells. β-actin served a loading control.
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the absence of mRNA, no EPHA4 protein expression was 
detected in the SS cell lines (Figure 1C). Unfortunately, 
EPHA4 protein expression could not be evaluated by 
immunohistochemistry in SS skin biopsies, since the 
EPHA4 antibody used in the Western Blot experiments 
was not suited for immunohistochemistry.
The kinase domain of EPHA4 is not 
phosphorylated in CD4+ T-cells in SS patients
EPHA4 is activated upon binding of its ligand by 
subsequent phosphorylation of the tyrosine residues in 
the juxtamembrane segment (Y596 and Y602) and kinase 
domain (Y779), where phosphorylation of the kinase 
domain is essential for full kinase activity [34]. To assay 
whether the overexpressed EPHA4 in SS cells is activated, 
Western blot analyses was performed using a specific 
antibody against a phosphorylated Y779 in the EPHA4 
kinase domain (EPHA4-pY779). The specificity of this 
antibody was verified by demonstrating detection of both 
commercial and in-house designed phosphorylated purified 
EPHA4 kinase domains [35, 36] (suppl. figure 1). None 
of the eight SS samples demonstrated phosphorylation 
of the kinase domain. In contrast, PC3 cells treated with 
pervanadate, a general phosphatase inhibitor, showed clear 
phosphorylation of EPHA4 (Figure 1B). 
We hypothesized that EPHA4 could be inactive 
in circulating SS cells due to little cell-cell contact, but 
could be activated in skin where increased cell-cell contact 
with other cells, such as keratinocytes and fibroblasts, is 
likely. We therefore investigated if phosphorylated EPHA4 
was detectable in six skin biopsies of SS patients using 
immunohistochemistry. Breast and prostate carcinoma, 
previously described as being positive for pEPHA4 [23, 
Figure 2: Phosphorylated EPHA4 expression in skin biopsies of SS patients. Skin biopsies from SS patients (n = 5) were stained 
with hematoxylin and eosin (HE; A., F.), and with antibodies against CD4 B., G., CD3 C., H. and phosphorylated EPHA4 (pEPHA4-Y779; 
D., E., I. and J.). Representative examples are shown. In none of the biopsies clear pEPHA-Y779 positive SS cells were observed.
Oncotarget31871www.impactjournals.com/oncotarget
25] were used as positive controls (results not shown), 
confirming the suitability of the pEHPA4-Y779 antibody 
for immunohistochemical analysis. In contrast, no clear 
positive staining was detected in CD4+ SS cells in SS 
skin biopsies (Figure 2A-2J). Thus, both peripheral blood 
and skin showed absence of phosphorylation of the kinase 
domain of EPHA4 in primary SS cells.
The EPHA4 kinase domain is resilient to 
phosphorylation on Y779 in CD4+ T-cells from 
SS patients and healthy controls
To investigate whether EPHA4 could be activated 
in vitro, SS cells of two patients were treated with the 
phosphatase inhibitor pervanadate and phosphorylation of 
Y779 was assayed over time (Figure 3). The effectiveness 
of pervanadate treatment of SS cells was confirmed 
by demonstrating rapid phosphorylation of STAT3. In 
contrast, phosphorylation of the EPHA4 kinase domain 
was not detectable after pervanadate treatment, even 
after 60 min of incubation. The experiment was repeated 
using CD4+ T-cells from a healthy donor, but again 
phosphorylation of pEPHA4-Y779 was not observed. In 
contrast, in PC3 cells clear phosphorylation was seen after 
pervanadate treatment (Figure 1B). 
DISCUSSION
In this study we were able to demonstrate 
overexpression of EPHA4 protein in primary CD4+ T-cells 
of SS patients compared to healthy controls. However, 
EPHA4 is not phosphorylated on its kinase domain, 
suggesting that EPHA4 kinase activity is not upregulated 
in these tumors.
Previously, genome-wide mRNA expression 
profiling studies by us and others have demonstrated that 
EPHA4 is highly upregulated in SS cells compared to 
other cutaneous lymphomas, such as mycosis fungoides 
(MF), benign forms of erythroderma and healthy controls 
[11-13]. In this study, we were able to correlate the high 
mRNA expression to high EPHA4 protein expression in 
SS cells compared to healthy CD4+ T-cells.
Holen et al. demonstrated that EPHA4 is expressed 
in CD4+ T-cells, more specifically in CD4+CD45RO+ 
memory T-cells [37]. As SS cells are skin-homing memory 
CD4+ CD45RO+ T-cells, the high EPHA4 expression in 
SS cells is in line with the higher numbers of CD45RO+ 
cells in SS patients compared to healthy controls. 
However, the expression of CD45RO+ by SS cells can 
vary and is also seen in neoplastic T cells in MF [38], 
which have low EPHA4 mRNA expression [11]. Thus 
Figure 3: Activation of EPHA4 in CD4+ T-cells in vitro. Cells were treated with pervanadate for the indicated time points 
(min) and were lysed for subsequent protein analysis with Western blot analysis. A. Expression of EPHA4 and phosphorylated EPHA4 
(pEPHA4-Y779) in PC3 cells, and CD4+ T-cells isolated from peripheral blood from one healthy control and two SS patients. B. 
phosphorylated STAT3 (pSTAT3) in CD4+ T-cells isolated from peripheral blood from one healthy.
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the high expression of EPHA4 appears to be specific for 
SS cells. Since all SS samples tested demonstrated high 
EPHA4 expression at protein level, this could serve as a 
novel marker for the diagnosis of Sézary syndrome. An 
ongoing diagnostic marker study is currently investigating 
the diagnostic value of potential SS markers, including 
EPHA4 mRNA expression.
We also investigated the activity of EPHA4 in 
SS cells by looking at the phosphorylation status of a 
critical tyrosine residue in the kinase domain of EPHA4. 
The catalytic and biological activities of EPH receptors 
(including EPHA4) are controlled by autophosphorylation 
on multiple residues, which include two tyrosines within 
a highly conserved juxtamembrane segment (JMS) and 
one in the kinase domain. It is known that the tyrosine 
in the kinase domain of an EPH receptor needs to be 
phosphorylated to have a fully active kinase function 
[34]. For EPHA4 this tyrosine is located at position 779 
(Y779). None of the peripheral blood CD4+ T-cells from 
SS patients or healthy controls showed phosphorylation of 
Y779 in the kinase domain of EPHA4. We hypothesized 
that absence of phosphorylated Y779 might be due to 
the lack of cell-cell contact in the peripheral blood and 
that activation might only occur when the tumor cells 
are present in the skin. However, no phosphorylatton of 
pEPHA4-Y779 was seen in CD4+ cells in SS skin samples 
to substantiate this hypothesis. 
Strikingly, we found that in vitro treatment of SS 
cells or healthy CD4+ T-cells with a general phosphatase 
inhibitor (pervanadate) could not induce phosphorylation 
of the EPHA4 kinase domain at Y779, whereas 
phosphorylation of another kinase, STAT3, was effectively 
induced in these cells. In contrast, pervanadate treatment 
of PC3 cells resulted in time dependent phosphorylation 
of the EPHA4 kinase domain at Y779. We analyzed 
the entire EPHA4 coding sequence, including the 
region encoding Y779, in primary SS cells of three SS 
patients for (inactivating) mutations, but no mutations 
were detected (data not shown). Other studies have 
demonstrated phosphorylation of EPHA4 in CD4+ T-cells 
after treatment with soluble ligands and identified several 
possible downstream targets [37, 39]. The difference in 
outcome between their and our study may relate to the 
fact that we specifically assayed phosphorylation of 
Y779 in the kinase domain of EPHA4, whereas others 
determine phosphorylation of all tyrosine residues. We 
therefore hypothesize that stimulation of CD4+ T-cells 
results in EPHA4 phosphorylation outside the kinase 
domain, which potentially results in a kinase without full 
activity [34]. The activation of downstream targets may 
be mediated via incomplete activation of EPHA4, or via 
cross activation of other (EPH) receptors. The fact that 
downstream targets were activated might suggest that 
partial activation is sufficient [37]. However, whether 
downstream target activation was mediated via EPHA4, 
or via cross activation by other (EPH) receptors cannot be 
determined. Therefore, further studies (e.g. using selective 
EPHA4 inhibitors) have to be conducted to investigate this 
phenomenon in more detail.
Since we have now established high expression 
of EPHA4, most likely without accompanying kinase 
activity, one can speculate whether upregulation of 
EPHA4 is a driver of SS development or merely a by-
stander effect of other oncogenic changes. EPHA4 has 
several transcription factor binding sites for STAT3 in its 
promoter, a transcription factor known to be constitutively 
activated in SS [8, 40]. In addition, the transcription factor 
TWIST1 is highly expressed in SS [11, 41], and EphA4 
was shown to be a down-stream effector for Twist1 in 
neural development in mice [42]. Taken together, these 
results suggest that enhanced expression of EPHA4 is 
most likely a bystander effect and the consequence of 
highly active transcription factors as TWIST and STAT3 
and is merely a by-product of oncogenic transformation. 
However, alternative, possible kinase-independent 
functions of EPHA4 cannot be excluded. 
In summary, we were able to demonstrate high 
EPHA4 protein expression in circulating SS cells, 
without phosphorylation of the kinase domain. The 
lack of phosphorylation suggests that EPHA4 is not 
functionally active in SS, at least not through classical 
kinase receptor signaling. Therefore it might not be an 
attractive therapeutic target for the treatment of SS as it 
is in other, mostly solid, tumors using small molecule 
inhibitors. Instead it could be used as a diagnostic marker 
to distinguish SS from other CTCLs or as a target for 
(monoclonal) antibodies. Further studies are required to 
investigate this and explore whether EPHA4 has other, 
kinase-independent functions or whether its upregulation 
is merely a result of the highly active transcription factors 
STAT3 and TWIST1.
MATERIALS AND METHODS
Patient material
SS patients (three males and five females, median 
age 68 years) were diagnosed on the basis of criteria 
of the World Health Organization (WHO)/European 
Organization for Research and Treatment of Cancer 
(EORTC) classification [2-4]. Patients with benign 
erythroderma (BE) secondary to psoriasis (n = 2) and 
atopic dermatitis (n = 2) and healthy donors (n = 4) were 
included as control groups.. Formalin-fixed, paraffin-
embedded (FFPE) skin biopsies from six SS patients 
and positive controls for immunohistochemistry (breast 
carcinoma and prostate carcinoma) were retrieved from 
the pathology archives of the Leiden University Medical 
Center.
Approval for these studies was obtained from 
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the Leiden University Medical Center review board, 
and informed consent was provided according to the 
Declaration of Helsinki Principles. All samples were 
handled in a coded fashion, following the medical ethical 
guidelines described in the Code ‘Proper Secondary Use 
of Human Tissue’ established by the Dutch Federation of 
Medical Sciences.
Antibodies
In this study the following antibodies were used: 
Rabbit-anti-EPHA4 (ECM Biosciences, Versailles, KY, 
USA); Rabbit-anti-EPHA4-pY779 (ECM Biosciences); 
Rabbit-anti-beta-actin (Cell Signaling Technology, 
Danvers, MA ,USA); Mouse-anti-CD3 (DAKO, Glostrup, 
Denmark), Mouse-anti-CD4 (Leica(Novo Castra), 
Newcastle Upon Tyne, UK); Goat-anti-mouse Ig-HRP 
(Pierce Scientific, Rockford, IL, USA); Goat-anti-rabbit 
Ig-HRP (Pierce Scientific); Goat-anti-rabbit Ig-biotin 
(Vector, Burlingame, CA, USA); Goat-anti-mouse Ig-
biotin (DAKO).
Cell lines
The SS cell lines HuT-78 (ATCC #TIB-161) 
and SeAx (kindly provided by Dr. K. Kaltoft) [29] and 
the prostate cancer cell line PC3 (ATCC #CRL-1435), 
were grown in HEPES buffered RPMI 1640 medium 
supplemented with 2 mM L-glutamine, 10% fetal bovine 
serum (FCS, HyClone, Thermo Scientific Rockford, IL 
USA), 100 Uml-1 penicillin, 100 mgml-1 streptomycin 
(both from Invitrogen, Carlsbad, CA, USA). For SeAx 
the medium was supplemented with 200 Uml-1 IL-2 
(PeproTech, Rocky Hill, NJ, USA). The authenticity of 
the cell lines was verified by short tandem repeat DNA 
profiling. 
CD4+ T-cell isolation and culturing
Peripheral blood mononuclear cells were isolated 
from heparinized blood by Ficoll density centrifugation. 
From the mononuclear cells, CD4 + T-cells were isolated 
by negative selection using magnetic beads (CD4+ 
T-cell isolation kit; Miltenyi Biotec, Bergisch Gladbach, 
Germany). Purity of the CD4+ T-cell population was 
generally > 85%, and > 90% of the isolated CD4+ T-cells 
in SS samples were SS cells, characterized by expression 
of a clonally rearranged T-cell receptor [30].
CD4+ T-cells were cultured in RPMI-1640 
supplemented with 10% human AB serum (Greiner 
Bio-One, Alphen aan den Rijn, The Netherlands), 2 
mM L-glutamine, 100 Uml-1 penicillin, 100 mgml-
1 streptomycin, 200 Uml-1 IL-2, and 5 ngml-1 IL-7 
(PeproTech).
Quantitative real time PCR (qPCR)
RNA was isolated from CD4+ T-cells from healthy 
controls, patients with SS or BE and the cell lines HuT-
78 and SeAx using the RNeasy mini kit (Qiagen, Hilden, 
Germany) and included on-column DNase treatment. 
From 1 µg total RNA, cDNA was synthesized using the 
iScriptTM cDNA Synthesis Kit (Bio-Rad, Veenendaal, the 
Netherlands) according to manufacturer’s instructions.
QPCR for EPHA4 mRNA and the reference genes 
(ARF5, ERCC3 and TMEM87A) with previous published 
primers [11, 31] were performed using the SYBR Green 
Supermix (Bio-Rad) on the CFX384™ real-time PCR 
detection system (Bio-Rad). The PCR-program included 
initialization (6 min at 95˚C), 45 cycles of denaturation 
(15s at 95˚C), annealing (30s at 60˚C) and elongation (30s 
at 72˚C), final elongation for 1 min at 72˚C and a DNA 
melting curve (55˚C to 95˚C through 0.2˚C increments 
every 10s). All samples were tested in duplicate.
EPHA4 expression was normalized based on 
the expression of the three reference genes using the 
normalization factor from geNorm [32]. The difference 
in EPHA4 expression between SS samples and the two 
control groups was analyzed with the Mann-Whitney test.
Pervanadate treatment
Pervanadate (100mM) was freshly made from 
vanadate and hydroxyperoxide (both Sigma-Aldrich, St. 
Louis, MO, USA) in 2 mM HEPES buffer pH = 7.3 as 
previously described [33]. The pervanadate was added to 
medium of the cells in 10mM final concentration. Cells 
were treated for the indicated time points before collection 
and subsequent lyses.
Western blot
Cells were lysed in M-PER supplemented with 
Halt protease inhibitor cocktail and phosphatase inhibitor 
cocktail (Thermo Scientific) using 23G needle and syringe 
and incubated on ice for at least 15 min. The lysates were 
cleared by centrifugation (18x103 x g for 20 min at 4°C). 
Protein concentration was determined by BCATM Protein 
assay (Pierce Scientific) and lysates were stored at -80°C.
Prior to separation by SDS-PAGE on a 8% gel, 7.5 
µg of total protein lysate was reduced in loading buffer 
containing dithiothreitol by boiling at 100ºC for 5 min. 
After transfer to methanol-activated polyvinylidene 
fluoride (PVDF) transfer membrane (Thermo Scientific) 
and blocking in 10% not-fat dry milk in Tris buffered 
saline with 0.1% Tween-20, membranes were incubated 
overnight at 4ºC under agitation with the primary 
antibodies. Subsequently the membranes were incubated 
with the appropriate HRP-linked secondary antibody for 
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1h at RT under agitation. Immunoblots were visualized 
by ECL (SuperSignal West Femto Maximum Sensitivity 
Substrate (Pierce Scientific)) and recorded on X-ray film.
Immunohistochemistry
Immunohistochemical staining was performed on 
4µm sections of FFPE samples using standard procedures. 
Antigen retrieval was performed by boiling for 10 min 
in 10mM citrate buffer (pH = 6.0) or in Tris (10mM)/
EDTA (1mM) (pH = 9.0) for phosphorylated EPHA4. 
Sections were incubated overnight at 4°C with the primary 
antibodies, followed by incubation with the appropriate 
biotinylated secondary antibody. The immunolabeling 
was detected by an streptavidin-biotin complex (GE 
Healthcare, Amersham, UK) and 3,3´-diaminobenzidine 
(Sigma-Aldrich) as a chromogen. Sections were 
counterstained with hematoxylin.
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